TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Radiograph measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mobility as measured by the SIGAM scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in 17-OH Pregnenolone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Postpartum Sleep Quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Sleep Durations
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Time to Intubate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Geometric Mean Titers of Neutralizing Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Intramuscular EMG of Lumbo-pelvic muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Visual change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Left Ventricular Ejection Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in Left Ventricular Filling Abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: WSRS improvement ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful delivery of the tympanostomy tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Visible fluorescence in regional lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Percentage of Participants Achieving a ≥ 50% Improvement in SALT50 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving a SALT50 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in analgesic intake measured in Defined Daily Dose (DDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain score on the Dolplus-2 pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in Wound Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percent Wounds Closed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of drug related signs of retinal degeneration
Endpoint domain: Adverse events/effects
Primary endpoint: Severe stoma specific morbidity rate
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change in Serum LDL-cholesterol Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of change in serum micro ribonucleic acid-122
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum-Tolerated Dose (MTD)
Endpoint domain: Adverse events/effects
Primary endpoint: Serum concentration of ingredients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS score of combined back and leg pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spatial localization and contrast images of breast abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: I-GERQ-R Success
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality of life (EQ-5D-5L scores)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: onset of clinical post-thrombotic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Individual relative Constant-Murley score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intake of additional antibiotic medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: MRI derived hypoxia scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene signature derived hypoxia scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Peak Enhancement (TTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Enhancement Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bone density measurements (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: End of surgery pocket swab culture positivity
Endpoint domain: Adverse events/effects
Primary endpoint: number of gad-enhancing lesions (CELs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: AUC from zero to infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in treatment outcome expectations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Major Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of patients with identified sliding sign and/or B lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain measured by mean VAS pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of confidence in delineating the area of interest
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Broncho-pulmonary dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Central venous oxygen saturation (ScvO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Catalase estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief from dry mouth
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intestinal de novo lipogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial exogenous, labelled palmitate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of clinics satisfying structure criteria
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients complying with process of care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients achieving target outcomes of care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual Risk Behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Frequency of major malformations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Frequency of minor congenital malformations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Corrected visual acuity ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in depression score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in anxiety score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in burnout level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With At Least 1 AE in Weeks 0-24
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Discontinued Study Therapy Due to AEs in Weeks 0-24
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Virologic Response (HIV-1 RNA < 40 Copies/mL) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum glucose response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Delay discounting rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Latency to relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dentin remineralization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity of Daily Living (ADL) motor ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 52-week PSA Complete Response (CR) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative Pupil Diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety as Measured by Treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: PaCO2 Variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: overall saliva cortisol level (AUCg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change from baseline FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline R5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in baseline exhaled nitric oxide (eNO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in exhaled nitric oxide (eNO) at 6h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline PWV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fear level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Urinary albumin creatinine ratio (ACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Positive Predictive Value and Negative Predictive Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Endpoint Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Gout Flares Per Subject
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early Virological Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: area under the plasma concentration curve from time of first dose to infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elimination half-life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of specific antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cellular B vaccine response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lung deposition by urinary measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Kinesia One Assessments Performed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Workflow in the operation room
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Urine growth factors level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low Density Lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient Trust in Physician
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Trust in Hospital
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accuracy of Patient Knowledge of their Physicians' Industry Relationships
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serological Evidence of Pertussis Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Retinol levels in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy and Tolerability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Patients With Ovarian Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Incidence of anesthesia-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of complete remission of thyroid cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pharmacological diabetes treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GCF levels of MMP-1, MMP-8, TGF-β1, VEGF and PDGF-AB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fraction of Patients With Reduction in CTCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total volume of intravenous hypertonic fluid administered
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of fallers
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiopulmonary function index change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Biopsy rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Physical activity measured by pedometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthy eating index quantified by the Food Frequency Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absentia due to diarrhea and/or respiratory-related illnesses
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of respiratory-related illnesses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of HCV antibody test completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clarke Error Grid Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Method bias in AbsCD4 and %CD4 measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Clinically Significant Change From Baseline in Physical and Neurological Examination Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 28-Days Seizure Rate at Month 12/Early Termination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Average Number of Injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Leicester Cough Questionnaire (LCQ)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of Patients With a Negative Mycological Culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from baseline hip flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Response rate of Everolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of CKD-385
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of CKD-385
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory complication or intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hemodynamic complication or intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Viable Specimens for Genetic Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Walking Index for Spinal Cord Injury version II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma susceptibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Airway remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: One-year target lesion failure (TLF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of office systolic and diastolic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decline of Hepatitis Delta Virus (HDV) RNA Quantitative Measurements >2 Logs at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Decline of Hepatitis Delta Virus (HDV) RNA Quantitative Measurement >2 Logs at 24 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Depression severity as measured by the HDRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perioperative opioid consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: frequencies of recurrence of UTI
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in UPDRS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cycle endurance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Otherwise unexplained fetal death occurring after 12 weeks gestation
Endpoint domain: Mortality/survival
Primary endpoint: Preterm delivery prior to 36 weeks' gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Proportion of patients developing gallstones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Early to atrial mitral flow velocity (E/A)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Wittener Panik Fragebogen (WPF)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cardiac Repolarization (Fredericia's QTc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Symptoms of Acute Stress Disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Patient satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Caregiver participation as measured by questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Caregiver participation as measured by attendance sheet
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fidelity as measured by weekly supervisor meeting
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Fidelity as measured by fidelity checklists
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: limb axis measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatherhood Development
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Dietary Risk Assessment (DRA) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Physical Activity Assessment (PAA) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behaviour Rating Inventory of Executive Functions (BRIEF)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Oral microbiota profiles - bacterial diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With 2-year Relapse Risk
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline of The WOMAC index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Superior allograft survival
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of periprocedural myocardial injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in lean mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brief Pain Inventory (Interference)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in skin barrier function assessed by TEWL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Prevention of Axial gastric rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevention of gastric leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Participants With Severe Oral Mucositis (WHO Grade 3-4)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Severe Oral Mucositis (CTCAE v. 4.0 Grade 3-5)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients with Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage change from baseline of lumbar vertebral BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Task performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Functional outcome after reconstructive surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new oral analgesic medications needed rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of catheters with bacterial contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Subjects Needing Airway Stent Placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes